Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danicamtiv in stable ambulatory primary dilated cardiomyopathy
2023-505492-68-00Phase 2Completed
- Sponsor
- MyoKardia
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label trial of danicamtiv in dilated cardiomyopathy (DCM) (3 cohorts), sponsored by MyoKardia. Primary endpoints: Clinical safety and tolerability in Part A and Clinically significant safety abnormalities in Part A. Started Oct 2020; status: completed.
02
Drugs
danicamtiv
03
Conditions
dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on 2023-505492-68-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505492-68-00.